Merrimack Pharmaceuticals Inc. To Present Phase 1 Data On MM-302 In Patients With Advanced HER2-Positive Breast Cancer
Published: Dec 06, 2013
CAMBRIDGE, Mass., Dec. 6, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Phase 1 data evaluating safety of the novel agent MM-302 in patients with advanced HER2-positive breast cancer will be presented at the 2013 San Antonio Breast Cancer Symposium (SABCS), December 10-14, 2013 in San Antonio, Texas.
Help employers find you! Check out all the jobs and post your resume.